Helen Torley, M.B. Ch. B., M.R.C.P., has been appointed president and chief executive officer of Halozyme, and will serve on the board of directors. Dr. Torley most recently served as executive vice president and chief commercial officer at Onyx Pharmaceuticals, a subsidiary of Amgen. She replaces Gregory I. Frost, Ph.D., who is leaving the company to become head of Intrexon’s health sector. Dr. Frost will continue to lead Halozyme’s scientific advisory board.    “Helen’s demon...